This financing will specifically support Fresenius Kabi's production of medical products and biosimilars across various European countries. The EIB-backed investment aims to bolster the resilience of pharmaceutical production within the EU, ensuring a more secure supply of essential medicines and providing financial relief to European healthcare systems.

Nicola Beer, Vice President of the EIB, said: "By supporting the accelerated development of biosimilar and generic pharmaceuticals by Fresenius across several European countries, we are helping to deliver innovative, affordable solutions for millions of patients while strengthening the EU's resilience in medicine supply and research excellence." 

Generic drugs are a crucial part of the healthcare landscape, accounting for approximately 70% of prescriptions in Europe while representing less than 20% of pharmaceutical costs. As a major producer of pharmaceuticals, biosimilars, clinical nutrition, and medical technologies, Fresenius operates around 20 manufacturing plants and multiple R&D centres throughout Europe. 

The company has invested over €1 billion in European manufacturing over the last five years, aligning with its "local-for-local" strategy to produce goods for European patients in Europe.